Literature DB >> 26230863

Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.

Maneesh Dave1, Kathan Mehta, Jay Luther, Anushka Baruah, Allan B Dietz, William A Faubion.   

Abstract

Recent advances in inflammatory bowel disease (IBD) therapeutics include novel medical, surgical, and endoscopic treatments. Among these, stem cell therapy is still in its infancy, although multiple studies suggest that the immunomodulatory effect of stem cell therapy may reduce inflammation and tissue injury in patients with IBD. This review discusses the novel avenue of stem cell therapy and its potential role in the management of ulcerative colitis and Crohn's disease. We conducted a comprehensive literature search to identify studies examining the role of stem cell therapy (without conditioning and immunomodulatory regimens) in IBD. Taken together, these studies suggest a promising role for stem cell therapy in IBD although the substantial challenges, such as cost and inadequate/incomplete characterization of effect, limit their current use in clinical practice.

Entities:  

Mesh：

Year:  2015        PMID： 26230863      PMCID： PMC4615553          DOI： 10.1097/MIB.0000000000000543

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN： 1078-0998            Impact factor:   5.325


  79 in total

1.  Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study.

Authors:  Marjolijn Duijvestein; Anne Christine W Vos; Helene Roelofs; Manon E Wildenberg; Barbara B Wendrich; Henricus W Verspaget; Engelina M C Kooy-Winkelaar; Frits Koning; Jaap Jan Zwaginga; Herma H Fidder; Auke P Verhaar; Willem E Fibbe; Gijs R van den Brink; Daniel W Hommes
Journal:  Gut       Date:  2010-10-04       Impact factor: 23.059

2.  Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue.

Authors:  Susanne Kern; Hermann Eichler; Johannes Stoeve; Harald Klüter; Karen Bieback
Journal:  Stem Cells       Date:  2006-01-12       Impact factor: 6.277

3.  Mesenchymal stromal cells derived from umbilical cord blood migrate in response to complement C1q.

Authors:  Yuanyuan Qiu; Leah A Marquez-Curtis; Anna Janowska-Wieczorek
Journal:  Cytotherapy       Date:  2012-01-23       Impact factor: 5.414

4.  Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo.

Authors:  Amelia Bartholomew; Cord Sturgeon; Mandy Siatskas; Karen Ferrer; Kevin McIntosh; Sheila Patil; Wayne Hardy; Steve Devine; David Ucker; Robert Deans; Annemarie Moseley; Ronald Hoffman
Journal:  Exp Hematol       Date:  2002-01       Impact factor: 3.084

Review 5.  Stem cells marked by the R-spondin receptor LGR5.

Authors:  Bon-Kyoung Koo; Hans Clevers
Journal:  Gastroenterology       Date:  2014-05-21       Impact factor: 22.682

Review 6.  The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease.

Authors:  Parambir S Dulai; Corey A Siegel
Journal:  Gastroenterol Clin North Am       Date:  2014-06-13       Impact factor: 3.806

7.  Adipose-derived mesenchymal stromal cells induce immunomodulatory macrophages which protect from experimental colitis and sepsis.

Authors:  Per Anderson; Luciana Souza-Moreira; Maria Morell; Marta Caro; Francisco O'Valle; Elena Gonzalez-Rey; Mario Delgado
Journal:  Gut       Date:  2012-05-25       Impact factor: 23.059

8.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

9.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

Authors:  Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2014-02       Impact factor: 22.682

10.  Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism.

Authors:  Farida Djouad; Louis-Marie Charbonnier; Carine Bouffi; Pascale Louis-Plence; Claire Bony; Florence Apparailly; Céline Cantos; Christian Jorgensen; Danièle Noël
Journal:  Stem Cells       Date:  2007-05-17       Impact factor: 6.277
View more
  34 in total

Review 1.  Can We Target Endogenous Anti-inflammatory Responses as a Therapeutic Strategy for Inflammatory Bowel Disease?

Authors:  Ross John Porter; Caroline Andrews; Daniel Paul Brice; Scott Kenneth Durum; Mairi Hall McLean
Journal:  Inflamm Bowel Dis       Date:  2018-09-15       Impact factor: 5.325

Review 2.  The role of adipose stem cells in inflammatory bowel disease: From biology to novel therapeutic strategies.

Authors:  Francesco De Francesco; Maurizio Romano; Laura Zarantonello; Cesare Ruffolo; Daniele Neri; Nicolò Bassi; Antonio Giordano; Giacomo Zanus; Giuseppe A Ferraro; Umberto Cillo
Journal:  Cancer Biol Ther       Date:  2016-07-14       Impact factor: 4.742

3.  Mesenchymal stem-cell therapy for perianal fistulas in Crohn's disease: a systematic review and meta-analysis.

Authors:  F Cheng; Z Huang; Z Li
Journal:  Tech Coloproctol       Date:  2019-07-08       Impact factor: 3.781

4.  Safety Studies for Use of Adipose Tissue-Derived Mesenchymal Stromal/Stem Cells in a Rabbit Model for Osteoarthritis to Support a Phase I Clinical Trial.

Authors:  Scott M Riester; Janet M Denbeigh; Yang Lin; Dakota L Jones; Tristan de Mooij; Eric A Lewallen; Hai Nie; Christopher R Paradise; Darcie J Radel; Amel Dudakovic; Emily T Camilleri; Dirk R Larson; Wenchun Qu; Aaron J Krych; Matthew A Frick; Hee-Jeong Im; Allan B Dietz; Jay Smith; Andre J van Wijnen
Journal:  Stem Cells Transl Med       Date:  2016-10-26       Impact factor: 6.940

Review 5.  Mechanisms of Disease: Inflammatory Bowel Diseases.

Authors:  Guilherme Piovezani Ramos; Konstantinos A Papadakis
Journal:  Mayo Clin Proc       Date:  2019-01       Impact factor: 7.616

6.  TSP-1-Mediated Induction of T Regulatory Cell by Adipose-Derived Mesenchymal Stem Cells: A Mechanism of Immunosuppression.

Authors:  Maneesh Dave
Journal:  Dig Dis Sci       Date:  2017-06-12       Impact factor: 3.199

7.  Mesenchymal Stem/Stromal Cell Therapy Is More Cost-Effective Than Fecal Diversion for Treatment of Perianal Crohn's Disease Fistulas.

Authors:  Sheeva Johnson; Jeffrey S Hoch; Wissam J Halabi; Jeffrey Ko; Jan Nolta; Maneesh Dave
Journal:  Front Immunol       Date:  2022-06-17       Impact factor: 8.786

8.  Ultrasound-guided Intracardiac Injection of Human Mesenchymal Stem Cells to Increase Homing to the Intestine for Use in Murine Models of Experimental Inflammatory Bowel Diseases.

Authors:  Maneesh Dave; Paola Menghini; Keiki Sugi; Rodrigo A Somoza; Zhenghong Lee; Mukesh Jain; Arnold Caplan; Fabio Cominelli
Journal:  J Vis Exp       Date:  2017-09-01       Impact factor: 1.355

9.  Filtrated Adipose Tissue-Derived Mesenchymal Stem Cell Lysate Ameliorates Experimental Acute Colitis in Mice.

Authors:  Takahiro Nishikawa; Keiko Maeda; Masanao Nakamura; Takeshi Yamamura; Tsunaki Sawada; Yasuyuki Mizutani; Takanori Ito; Takuya Ishikawa; Kazuhiro Furukawa; Eizaburo Ohno; Ryoji Miyahara; Hiroki Kawashima; Takashi Honda; Masatoshi Ishigami; Tokunori Yamamoto; Seiji Matsumoto; Yuji Hotta; Mitsuhiro Fujishiro
Journal:  Dig Dis Sci       Date:  2020-06-01       Impact factor: 3.199

10.  A novel therapeutic approach for inflammatory bowel disease by exosomes derived from human umbilical cord mesenchymal stem cells to repair intestinal barrier via TSG-6.

Authors:  Shaopeng Yang; Xiaonan Liang; Jia Song; Chenyang Li; Airu Liu; Yuxin Luo; Heran Ma; Yi Tan; Xiaolan Zhang
Journal:  Stem Cell Res Ther       Date:  2021-05-29       Impact factor: 6.832
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.